The reversal removes a significant legal barrier for Teva's breach-of-contract claim against Lilly. Monitor for discovery developments and potential settlement discussions; a favorable outcome could unlock damages from lost generic Forteo sales during the exclusivity period. The case now proceeds to merits discovery.
Price Chart
Executive Summary
The Seventh Circuit reversed the district court's dismissal of Teva's breach-of-contract claim against Eli Lilly, holding that Teva plausibly alleged Lilly violated a 2018 settlement agreement by seeking additional regulatory exclusivity that blocked Teva's generic Forteo entry. The case is remanded for further proceedings, reviving Teva's claim that Lilly's covenants not to obstruct generic competition survived the expiration of the underlying patents.
Court Ruling Details
Key Facts
- Seventh Circuit reversed dismissal of Teva's breach-of-contract claim against Eli Lilly
- Teva alleged Lilly violated a 2018 settlement agreement by obtaining 3 years of additional regulatory exclusivity (Nov 2020–Nov 2023) that blocked Teva's generic Forteo entry
- District court had ruled the settlement agreement expired when Forteo patents expired (Aug 19, 2019); Seventh Circuit found the agreement's duration is a factual question not resolvable on the pleadings
- Teva's covenant not to sue and other provisions plausibly survived patent expiration, supporting that Lilly's non-obstruction covenant also remained in effect
- Case remanded for further proceedings on the merits
Financial Impact
Potential damages from lost generic Forteo market access during Nov 2020–Nov 2023 exclusivity period; no dollar amount stated in the opinion
Risk Factors
- Teva must still prove breach, causation, and damages on remand
- Lilly may seek interlocutory appeal or certiorari
- Litigation could extend for years with uncertain outcome
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-25219da5fd-TEVA |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.31 (+8.14%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.31 (+6.93%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.31 (+4.85%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.31 (+7.87%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.31 (+3.17%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.31 (+3.17%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.31 (+8.77%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.31 (+12.92%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.31 (+12.28%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.31 (+13.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access